|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009325,
umls-concept:C0021469,
umls-concept:C0021755,
umls-concept:C0021760,
umls-concept:C0024432,
umls-concept:C0033268,
umls-concept:C0224522,
umls-concept:C0384648,
umls-concept:C0392756,
umls-concept:C0442805,
umls-concept:C0597357,
umls-concept:C1334108,
umls-concept:C1456820,
umls-concept:C1515654,
umls-concept:C1749467,
umls-concept:C1825592,
umls-concept:C1879547,
umls-concept:C1883712
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2002-7-15
|
|
pubmed:abstractText |
To evaluate the usefulness of combination treatment with cytokine inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/CCL20 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CCR6 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL20,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CC,
http://linkedlifedata.com/resource/pubmed/chemical/IL17RA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Macrophage Inflammatory Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR6,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-17,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
730-3
|
|
pubmed:dateRevised |
2008-11-20
|
|
pubmed:meshHeading |
pubmed-meshheading:12117682-Adult,
pubmed-meshheading:12117682-Aged,
pubmed-meshheading:12117682-Aged, 80 and over,
pubmed-meshheading:12117682-Biological Markers,
pubmed-meshheading:12117682-Chemokine CCL20,
pubmed-meshheading:12117682-Chemokines, CC,
pubmed-meshheading:12117682-Female,
pubmed-meshheading:12117682-Humans,
pubmed-meshheading:12117682-Interleukin-6,
pubmed-meshheading:12117682-Macrophage Inflammatory Proteins,
pubmed-meshheading:12117682-Male,
pubmed-meshheading:12117682-Middle Aged,
pubmed-meshheading:12117682-Monocytes,
pubmed-meshheading:12117682-Receptors, CCR6,
pubmed-meshheading:12117682-Receptors, Chemokine,
pubmed-meshheading:12117682-Receptors, Interleukin,
pubmed-meshheading:12117682-Receptors, Interleukin-1,
pubmed-meshheading:12117682-Receptors, Interleukin-17,
pubmed-meshheading:12117682-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:12117682-Recombinant Proteins,
pubmed-meshheading:12117682-Synovial Membrane
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation.
|
|
pubmed:affiliation |
Department of Immunology, Hôpital E Herriot, 69437 Lyon Cedex 03, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
